Results 21 to 30 of about 947,345 (358)

Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]

, 2008
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad, Daley, George, Gray, Nathanael, KURIYAN, John, Seeliger, Markus   +4 more
core   +1 more source

Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer. [PDF]

, 2014
Somatic mutations of the epidermal growth factor receptor often cause resistance to therapy with tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC). In this study, we aimed to identify partner drugs and pathways that can induce cell death in
Koeffler, H Phillip, Leong, Geraldine, Madan, Vikas, Mori, Seiichi, Sudo, Makoto, Yang, Henry   +5 more
core   +4 more sources

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

Haematologica, 2011
Background Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia.
Benjamin Hanfstein, Martin C. Müller, Sebastian Kreil, Thomas Ernst, Thomas Schenk, Christian Lorentz, Uwe Schwindel, Armin Leitner, Rüdiger Hehlmann, Andreas Hochhaus   +9 more
doaj   +1 more source

The nucleotide and partial amino acid sequences of rat fetuin [PDF]

, 1992
Fetuins are among the major plasma proteins, yet their biological role has remained elusive. Here we report the molecular cloning of rat fetuin and the sequence analysis of a full-length clone, RF619 of 1456 bp with an open reading frame of 1056 bp ...
Albrecht G. J., Brown W. M., Cam A., Cayatte A. J., Christie D. L., Cohen P., Colclasure G. C., Coughlin J. P., Davis L. G., Dziegielewska K. M., Dziegielewska K. M., Dziegielewska K. M., Edge A. S. B., Haasemann M., Heijne G., Hortin G., Jones S. E., Kellermann J., Laemmli U. K., Lee C. C., Lewis J. G., Mizuno M., Mollgard K., Muller-Esterl W., Oss C. J., Pedersen K. O., Puck T. T., Rawlings N. D., Rohrlich S. T., Sambrook J., Sanger F., Sbraccia P., Schultze H. E., Strauss E. C., Triffitt J. T., Yang F., Yet M. G.   +36 more
core   +1 more source

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Journal of Hematology & Oncology, 2018
Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
Guoshuang Shen, F. Zheng, Dengfeng Ren, F. Du, Qiuxia Dong, Ziyi Wang, Fuxing Zhao, Raees Ahmad, Jiuda Zhao   +8 more
semanticscholar   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

Clinical Cancer Research, 2018
Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-positive non–small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs. Acquired EGFR C797S mutation has
Zhe Yang, N. Yang, Q. Ou, Y. Xiang, T. Jiang, Xue Wu, H. Bao, X. Tong, Xiaonan Wang, Y. Shao, Yunpeng Liu, Yan Wang, Caicun Zhou   +12 more
semanticscholar   +1 more source

Nilotinib-Associated Destructive Thyroiditis

Case Reports in Endocrinology, 2015
Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia.
Suhalia Bakerywala, Monica D. Schwarcz, Michael D. Goldberg, Guy Valiquette, Irene A. Weiss   +4 more
doaj   +1 more source

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. [PDF]

, 2014
Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Bhardwaj, G, Changou, C, Chintapalli, S, Evans, CP, Guo, W, Kumaresan, P, Kung, H-J, Lam, KS, Liu, R, Ma, A-H, Mazloom, A, Patterson, R, Sanchez, E, Xiao, K, Xiao, W, Yang, JC, Yeh, C-T   +16 more
core   +2 more sources

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Haematologica, 2013
There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative ...
Antonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, Luigiana Luciano, Antonella Gozzini, Mario Annunziata, Bruno Martino, Fabio Stagno, Francesco Cavazzini, Mario Tiribelli, Giuseppe Visani, Patrizia Pregno, Pellegrino Musto, Carmen Fava, Nicola Sgherza, Francesco Albano, Gianantonio Rosti, Giuliana Alimena, Giorgina Specchia   +19 more
doaj   +1 more source